|
|
|
Issue Open Date
|
20-Dec-24
|
|
|
|
Issue Closing Date
|
24-Dec-24
|
|
|
|
Application Money
|
100
|
|
|
|
Allotment Money
|
|
|
|
|
|
|
|
Price Band
|
372
-
391
|
|
|
|
Minimium Application No.
|
38
|
|
|
|
Issue Size (Shares)
|
8534681
|
|
|
|
Market Lot
|
1
|
|
|
|
|
|
Objective
|
|
1.Investment in one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility.2.Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company.3.Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary.4.Funding the working capital requirements of our Company.5.Investment in our Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements.6.Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
|
|
|
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
|
Offered / Reserved |
Bid For |
|
|
Non-Institutional Investors
|
2319879
|
222963632
|
96.1100264281025
|
|
Qualified Institutional Buyers
|
4593216
|
434778102
|
94.6565765685742
|
|
Retail Individual Investors
|
1546586
|
137996278
|
89.2263850830151
|
|
|
|
|
Business Description
We are a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Our strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing us as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, we strategically identify commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets. We leverage our R&D capabilities to develop and manufacture a portfolio of differentiated complex pharmaceutical products. Our focus on quality and our ability to identify specialty and complex molecules has resulted in an extensive pipeline of curated complex products spanning diverse dosage forms and therapeutic domains, demonstrated through our partnerships in the Regulated Markets with prominent foreign and Indian pharmaceutical companies including Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories Limited, Sun Pharmaceuticals Industries Limited, Dr. Reddy’s Laboratories Inc. and Cipla USA Inc.
|
|
|
Promoter's Holding
|
|
|
|
Total Share Capital
|
22176079
|
|
|
|
Offered to Public
|
8534681
|
|
|
|
Promoter's Holding (Pre-Issue)
|
66.67
|
|
|
|
Promoter's Holding (Post-Issue)
|
|
|
|
|
|
|
|
|
|
|
|
Address |
1101 To 1103
11th Floor
South Tower
One 42 Opp. Jayantilal Park
Ambali Bopal Road
Ahmedabad,
Gujarat,
380054
Phone : 079-29999857
Email : cs@senorespharma.com
Website : www. senorespharma.com
|
|
|
Registrar |
Link Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
|
|
|
Listed at |
|
BSE, NSE
|
|
|
Lead Manager |
Ambit Pvt Ltd.
Equirus Capital Pvt Ltd
Nuvama Wealth Management Ltd.
|
|
|
Promoters |
Ashokkumar Vijaysinh Barot
Swapnil Jatinbhai Shah
|
|
